These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33549099)

  • 1. Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility.
    Lee SM; Kim HJ; Suh D; Joung KI; Kim ES; Back HJ; Kwon JY; Park MJ; Suh DC
    BMC Health Serv Res; 2021 Feb; 21(1):126. PubMed ID: 33549099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of patent expiry on drug prices: insights from the Dutch market.
    van der Schans S; Vondeling GT; Cao Q; van der Pol S; Visser S; Postma MJ; Rozenbaum MH
    J Mark Access Health Policy; 2020 Dec; 9(1):1849984. PubMed ID: 33312457
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
    Lee HJ; Han E; Kim H
    Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses.
    Serra-Burriel M; Martin-Bassols N; Perényi G; Vokinger KN
    JAMA Health Forum; 2024 Aug; 5(8):e242530. PubMed ID: 39150730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of generic antiretrovirals in France for HIV patients' care: a simulation between 2019 and 2023.
    Demeulemeester R; Savy N; Mounié M; Molinier L; Delpierre C; Dellamonica P; Allavena C; Pugliesse P; Cuzin L; Saint-Pierre P; Costa N
    BMC Health Serv Res; 2022 Apr; 22(1):567. PubMed ID: 35477443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?
    Son KB
    Front Public Health; 2023; 11():1120729. PubMed ID: 37601172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating Potential for Drug Budget Reallocation Following Expiration of Exclusivity of Pharmaceutical Products.
    Toghanian S; Moshtaghi-Svensson J; Papageorgiou M; Kittelsen K; Dolk C; Hultstrand M; Salomonsson S
    J Health Econ Outcomes Res; 2022; 9(1):20-30. PubMed ID: 35178466
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
    Kwon HY; Kim H; Godman B; Reich MR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy).
    Restelli U; Scolari F; Bonfanti P; Croce D; Rizzardini G
    BMC Infect Dis; 2015 Aug; 15():323. PubMed ID: 26259842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review.
    Vondeling GT; Cao Q; Postma MJ; Rozenbaum MH
    Appl Health Econ Health Policy; 2018 Oct; 16(5):653-660. PubMed ID: 30019138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis.
    Chapman SR; Aladul MI; Fitzpatrick RW
    BMJ Open; 2019 Aug; 9(8):e026817. PubMed ID: 31375605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel methodology for pharmaceutical expenditure forecast.
    Vataire AL; Cetinsoy L; Aballéa S; Rémuzat C; Urbinati D; Kornfeld Å; Mzoughi O; Toumi M
    J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Market Exclusivity of the Originator Drugs in South Korea: A Retrospective Cohort Study.
    Son KB
    Front Public Health; 2021; 9():654952. PubMed ID: 33889560
    [No Abstract]   [Full Text] [Related]  

  • 18. Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone.
    Rome BN; Egilman AC; Patel NG; Kesselheim AS
    Value Health; 2023 Mar; 26(3):370-377. PubMed ID: 36266218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.